The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Official Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Pertuzumab (rhuMAb 2C4) in Combination With Gemcitabine and the Effect of Tumor-Based HER2 Activation in Subjects With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study ID: NCT00096993
Brief Summary: This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of pertuzumab in combination with gemcitabine relative to placebo in combination with gemcitabine in subjects with advanced ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Univ. of Alabama at Birmingham, Birmingham, Alabama, United States
Comprehensive Cancer Institute, Huntsville, Alabama, United States
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
Arizona Cancer Center, Tucson, Arizona, United States
Alta Bates Comp. Cancer Ctr, Berkeley, California, United States
California Cancer Crae, Inc, Greenbrae, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Ventura County Hematology Oncology Specialists, Oxnard, California, United States
Sutter Cancer Center, Sacramento, California, United States
Southern California Permanente Medical Group (Kaiser), San Diego, California, United States
Sharp Healthcare, San Diego, California, United States
Norwalk Medical Group, Norwalk, Connecticut, United States
Hematology Oncology, P.C., Stamford, Connecticut, United States
Integrated Community Oncology Network, Jacksonville, Florida, United States
Florida Hospital, Orlando, Florida, United States
Memorial Health Univ. Med. Ctr., Savannah, Georgia, United States
St. Luke's Mountain States Tumor Institute, Boise, Idaho, United States
North Idaho Cancer Center, Coeur d'Alene, Idaho, United States
University Of Chicago, Chicago, Illinois, United States
Carle Clinic Association, Urbana, Illinois, United States
Indiana University, Indianapolis, Indiana, United States
St. Vincent Hospital, Indianapolis, Indiana, United States
Cancer Center of Kansas, Wichita, Kansas, United States
University of Kentucky, Lexington, Kentucky, United States
Greater Baltimore Medical Center, Baltimore, Maryland, United States
Franklin Square Hospital Center, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Wayne State Univ. Barbara Ann Karmanos Cancer Inst., Detroit, Michigan, United States
Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
Cooper Health System, Voorhees, New Jersey, United States
Carolinas Medical Center, Charlotte, North Carolina, United States
Ohio State University College of Medicaine, Columbus, Ohio, United States
Pelvic Surgery Assoc., Columbus, Ohio, United States
Oklahoma Univ. Medical Center, Oklahoma City, Oklahoma, United States
Corvallis Clinic, Corvallis, Oregon, United States
Kaiser Permanente Northwest Division, Portland, Oregon, United States
Womens and Infants Hospital, Providence, Rhode Island, United States
Northern Virginia Pelvic Surgery Assoc., Annandale, Virginia, United States
Carilion Gyn/Onc, Roanoke, Virginia, United States
Name: Virginia Patton, M.D.
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR